Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
| 4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
| 4/8/2024 | Buy | TD Cowen | |
| 4/3/2024 | $12.00 | Outperform | Wedbush |
| 1/16/2024 | $18.00 → $9.00 | Buy → Hold | Stifel |
| 12/8/2023 | $10.00 | Neutral | Citigroup |
| 10/9/2023 | $19.00 | Outperform | BMO Capital Markets |
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
-- Presented initial in vivo data for universal liver-targeted LNP and Wilson's Disease program at ESGCT; initiated IND-enabling activities for Wilson's Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments -- -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- Unveiled strategically focused pipeline, prioritizing set of high value programs, each with a clearly defined path to value creation and the potential to a
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation Conference: Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024, at 1:15 p.m. ET in New York, NY.Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 19, 2024 at 2:30 p.m. GMT (9:30 a.m. ET) in London, U.K. Live audio webcasts
Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND and/or CTA filing expected in 1H 2026 CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today presented data from multiple studies showcasing the potential of its proprietary, universal lipid nanoparticle (LNP) platform to precisely deliver Prime Editor
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
H.C. Wainwright initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $10.00
Citigroup upgraded Prime Medicine from Neutral to Buy and set a new price target of $10.00
Chardan Capital Markets initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $17.00
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. "I am delighted to welcome Allan to Prime Medicine. He brings tremendou
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's second patent, No. 11,643,652, and allowed third patent application, No. 17/751,599 -- -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 -- CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME)